Jun 4, 2021 · Wegovy™ is the first and only once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist therapy approved for weight management for people living with obesity. The …

Bagsværd, Denmark, 22 May 2023 – Novo Nordisk today announced headline results from OASIS 1, a phase 3a trial in the global OASIS programme. OASIS 1 is a 68-week, efficacy …

Sep 20, 2019 · Rybelsus ®, the brand name for oral semaglutide in the US, is the first approved glucagon-like peptide-1 (GLP-1) receptor agonist in a tablet. The approval of Rybelsus ® is …

Sources: Patient data is Novo Nordisk estimates; Value data: 2018 and 2021 data based on company reported sales for insulin, GLP-1, SGLT-2i and DPP-4i and IQVIA data for traditional …

• Novo Nordisk continues to be the global market leader in the GLP-1 segment with a 54.8% value market share • Estimated global GLP-1 share of total diabetes

Novo Nordisk A/S Novo Alle 1 2880 Bagsværd Denmark +45-4444-8888 CVR-no. 24256790 Our medicines are for the approved indication for which they are authorised in the local country or …

GLP-1 class expansion accelerates in the US in the first quarter of 2023 with volume growth across our portfolio NBRx: New-to-brand prescriptions; TRx: Total prescriptions; NN: Novo …

Our history spans a century and it all began with two small Danish companies, Nordisk Insulinlaboratorium and Novo Terapeutisk Laboratorium. After hearing of the discovery of …

• Novo Nordisk continues to be the global market leader in the GLP-1 segment with a 55.6% value market share • Estimated global GLP-1 share of total diabetes prescriptions

Jun 24, 2024 · Novo Nordisk announces 4.1 billion USD investment to expand US manufacturing capacity. In 2024, Novo Nordisk plans to boost its current investments, aiming to allocate USD …